Evidence map›Paper›PMID 39896608›Full record

ArticlebioRxiv : the preprint server for biology2025

Druggable genome CRISPRi screen in 3D hydrogels reveals regulators of cortactin-driven actin remodeling in invading glioblastoma cells.

Mufeng Hu, Anna Weldy, Isabella Lovalvo, Erin Akins, Saket Jain, Alexander Chang, Ankita Sati, Meeki Lad, Austin Lui, Akhil Rajidi and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Mufeng HuUniversity of California San Francisco (UCSF) Neurosurgery.
Anna WeldyUC Berkeley Chemical and Biomolecular Engineering.
Isabella LovalvoUniversity of California San Francisco (UCSF) Neurosurgery.
Erin AkinsUniversity of California, Berkeley (UC Berkeley) Bioengineering.
Saket JainUniversity of California San Francisco (UCSF) Neurosurgery.
Alexander ChangUniversity of California San Francisco (UCSF) Neurosurgery.
Ankita SatiUniversity of California San Francisco (UCSF) Neurosurgery.
Meeki LadUniversity of California San Francisco (UCSF) Neurosurgery.
Austin LuiUniversity of California San Francisco (UCSF) Neurosurgery.
Akhil RajidiUniversity of California San Francisco (UCSF) Neurosurgery.
Ameya KothekarUniversity of California San Francisco (UCSF) Neurosurgery.
Erika DingUC Berkeley Chemical and Biomolecular Engineering.
Sanjay KumarUC Berkeley Chemical and Biomolecular Engineering.
Manish K AghiUniversity of California San Francisco (UCSF) Neurosurgery.

Funding

Tumor cell and microenvironment changes causing antiangiogenic therapy resistanceR01NS079697 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2013 to 2021
$3.2M
Biophysical Control of Cell Form and Function by Single Actomyosin Stress Fibers: Instrument SupplementR01GM122375 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI KUMAR, SANJAY · 2017 to 2025
$2.7M
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systemsR01CA227136 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2018 to 2022
$2.2M
Retroviral RLI immunomodulatory gene therapy for glioblastomaR01NS123808 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Manish Aghi · 2022 to 2026
$2.1M
Mechanisms of adhesion and invasion in hyaluronic acid matricesR01CA260443 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI KUMAR, SANJAY · 2021 to 2025
$1.8M
NCI NIH HHS R01 CA227136NCI NIH HHS R01 CA260443NIGMS NIH HHS R01 GM122375NINDS NIH HHS R01 NS079697NINDS NIH HHS R01 NS123808
6 · The paper itself

Abstract

To identify new therapeutic targets that limit glioblastoma (GBM) invasion, we applied druggable-genome CRISPR screens to patient-derived GBM cells in micro-dissectible biomimetic 3D hydrogel platforms that permit separation and independent analysis of core vs. invasive fractions. We identified 12 targets whose suppression limited invasion, of which ACP1 (LMW-PTP) and Aurora Kinase B (AURKB) were validated in neurosphere assays. Proximity labeling analysis identified cortactin as an ACP1-AURKB link, as cortactin undergoes serine phosphorylation by AURKB and tyrosine dephosphorylation by ACP1. Suppression of ACP1 or AURKB in culture and

Indexed as

CRISPRGlioblastomaHydrogelsInvasionMetabolism

Identifiers

PMID39896608
PMCPMC11785026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.